** Analysts at Jefferies downgrade rating to "hold" from "buy" on New Zealand's Fisher & Paykel Healthcare FPH.NZ
** Jefferies says it is interested in knowing the impacts FPH has faced from U.S. tariffs to date, when it reports FY25 results on May 28; to keep a close eye on co's mitigation strategies
** However, brokerage keeps PT unchanged at NZ$39.40 per share
** We understand the primary impact on FPH imports is currently a 10% tariff on New Zealand products — brokerage
** One of 12 analysts rate the stock "buy" or higher, nine "hold" and two "sell" or lower; their median PT is NZ$35.81, according to data compiled by LSEG
** Stock has fallen 4.3% this year, as of last close
(Reporting by Roshan Thomas in Bengaluru)
((Roshan.Thomas@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。